, Volume 23, Issue 7, pp 743–744 | Cite as

The authors’ reply

  • Andrew Moore
  • Ceri Phillips
  • Elke Hunsche
  • James Pellissier
  • Simone Crespi


Rheumatoid Arthritis Misoprostol Etoricoxib Claim Database Health Economic Analysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Moore A, Phillips C, Hunsche E, et al. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis in the UK. Pharmacoeconomics 2004; 22 (10): 643–60PubMedCrossRefGoogle Scholar
  2. 2.
    Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 18 Suppl. 28: 6–10Google Scholar
  3. 3.
    National Institute for Clinical Excellence. Guidance on the use Gasof cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. Technology Appraisals Process Series No 27. London, England: NICE 2001 June Report No.: N0016Google Scholar
  4. 4.
    Hunt RH, Barkun AN, Baron D, et al. Recommendations for the appropriate use of anti-inflammatory drugs in the era of coxibs: defining the role of gastroprotective agents. Can J Gastroenterol 2002; 16 (4): 231–40PubMedGoogle Scholar
  5. 5.
    Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003; 49 (3): 283–92PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Andrew Moore
    • 1
  • Ceri Phillips
    • 2
  • Elke Hunsche
    • 3
  • James Pellissier
    • 4
  • Simone Crespi
    • 5
  1. 1.Pain Research, The ChurchillHeadington, OxfordUK
  2. 2.School of Health and Science, Centre for Health Economics and Policy StudiesUniversity of Wales SwanseaSwansea, WalesUK
  3. 3.Outcomes Research, Merck & Co., Inc.Whitehouse StationUSA
  4. 4.Health Economic Statistics, Merck Research LaboratoriesMerck & Co., Inc.Blue BellUSA
  5. 5.Rutgers UniversityNew BrunswickUSA

Personalised recommendations